Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries.
The fresh blow to Roche’s hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on May 11, but the latest setback is not the end of the road for these oncology treatments, analysts say.
Development of a new cancer treatment pioneered by Roche was thrown into doubt on May 11 when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker’s shares.
Roche warned that Russia’s attack on Ukraine is disrupting the development of a new generation of multiple sclerosis (MS) drugs as the industry has come to disproportionately rely on Eastern Europe for clinical trials.
Roche’s first-quarter 2022 sales rose 10 percent on strong U.S. demand for rapid COVID-19 antigen tests and specialty drugs but the Swiss drugmaker reaffirmed that a drop in pandemic-related demand would put the brakes on growth.
Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Roche/Genentech’s Avastin. The biosimilar approval marks the second for Amneal during 2022.
The Precision Cancer Consortium (PCC) announced its formation as a new collaboration of pharmaceutical companies with a shared vision of enabling access to comprehensive testing for all cancer patients globally.
Eisai Co. Ltd. and Eli Lilly and Co. on April 8 said they still plan to seek accelerated U.S. approval for experimental Alzheimer’s drugs even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.
Interim data from Roche Group member Genentech’s first randomized study of a candidate treatment for extensive-stage small cell lung cancer (ES-SCLC) failed to meet the clinical trial’s co-primary endpoint against the hard-to-treat disease.
Roche partnered with Bristol Myers Squibb to utilize two digital pathology platforms that would advance research into treatment options for patients diagnosed to have solid tumors.